Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...
Omeros Corporation (NASDAQ:OMER) Q4 2025 Earnings Call Transcript April 1, 2026 Operator: Good afternoon, and welcome to today’s earnings call for Omeros Corporation. [Operator Instructions] Please be ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — SEATTLE--(BUSINESS WIRE)--Omeros ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
A stem cell transplant usually requires you to stay in the hospital for weeks and get frequent checkups for months after you go home. Close monitoring lets your health care team support your recovery ...
Narsoplimab is a human monoclonal antibody that specifically targets mannan-binding lectin-associated serine protease-2. The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) ...
What Is Yartemlea, and Why Does It Matter? Yartemlea (narsoplimab-wuug) is a new medicine approved by the FDA for treating a rare and serious condition called transplant-associated thrombotic ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic ...
The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results